70 vaccines in the works, with three leading candidates, says WHO

The drug industry is hoping to compress the time it takes to get a vaccine to market - usually about 10 to 15 years - to within the next year

coronavirus, China
Travellers line up with their belongings outside Hankou Railway Station after travel restrictions to leave Wuhan, the capital of Hubei province and China's epicentre of the novel coronavirus disease (COVID-19) outbreak, were lifted. Photo: Reuters
Bloomberg
2 min read Last Updated : Apr 14 2020 | 1:43 AM IST
There are 70 coronavirus vaccines in development globally, with three candidates already being tested in human trials, according to the World Health Organization (WHO), as drugmakers race to find a cure for the deadly pathogen.

The furthest along in the clinical process is an experimental vaccine developed by Hong Kong-listed CanSino Biologics Inc. and the Beijing Institute of Biotechnology, which is in phase 2. The other two being tested on humans are treatments developed separately by US drugmakers Moderna  and Inovio Pharmaceuticals , according to a WHO document.
 
Progress is occurring at unprecedented speed in developing vaccines as the infectious pathogen looks unlikely to be stamped out through containment measures alone. The drug industry is hoping to compress the time it takes to get a vaccine to market — usually about 10 to 15 years — to within the next year.
 
Drugmakers, big and small, have jumped in to try to develop a vaccine, which would be the most effective way to contain the virus. Pharmaceutical giants like Pfizer Inc. and Sanofi have vaccine candidates in the preclinical stages, according to a WHO document.

ADB announces $20-bn virus rescue package
 
The Asian Development Bank said Monday it will roll out a massive $20-billion package to help developing member nations weather the economic fallout from the coronavirus pandemic.
 
The fund represents the tripling of a package announced just a month ago, which ADB decided to boost as the scale of the contagion’s impact has mushroomed. Nearly simultaneous shutdowns across the global economy, with workers ordered to hunker down at home against the virus, have set the stage for a deep recession.

(AFP | PTI)

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusLockdownWorld Health OrganizationAsian Development Bank

Next Story